Glenn A. Doyle, Phd Email & Phone Number

Philadelphia, Pennsylvania, United States

Immuno-Oncology research and development.

Philadelphia, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Provided scientific leadership, technical training, and mentoring under 8 NIH research grants (up to 3 simultaneously) to research team of 1 visiting professor, 5 post-docs, 3 grad/12 undergrad students, and 6 research techs. Collaborated with up to 4 other research teams at UPenn and with 4 external professors/2 grad students.* Mobile DNA / Bioinformatics. Studied mobile DNA in psychiatric & neurologic disorders using targeted NGS....Collaborated with other researchers to develop / expand use of key techniques including FACS separation of neuronal/non-neuronal nuclei, L1seq, and custom bioinformatics pipeline....Combined 2 techniques (SIMPLE & L1seq) to develop REBELseq. Enabled 600% improvement in efficiency for HT analysis by substantially decreasing time to produce sequencing libraries.* Bipolar Disorder/ANK3. Identified rare variants in ANK3 gene by re-sequencing (NGS & Sanger) exons.* Nicotine Addiction. Showed allelic imbalance of CHRNA5 is related to particular promoter haplotypes that may be related to nicotine behaviors in humans. Identified rare deletion variant in CHRNA5 related to increased individual smoking behavior.* Opioid Use Disorder (OUD). Studied genetics of opioid use behaviors in mice & humans....Discovered pharmacogenetic marker in human OPRM1 predictive of methadone treatment response....Identified differential expression of Rgs17, a protein that regulates μ-opioid receptor signaling, in mice with disparate oral morphine self-administration....Participated in Geisinger collaboration for genome-wide association study of OUD.* Authored 9 manuscripts, 8 original NIH grant proposals, and 3 in-house grant proposals. Provided pre-submission review for 20 NIH grant proposals by 7 colleagues and peer-reviewed 10 manuscripts for 9 journals.* Presented results at UPenn seminars, at 1 local / 3 national meetings of The Society for Neuroscience, & at 1 national meeting of the American Epilepsy Society.

Philadelphia, Pennsylvania, United States

Simultaneously consulted on multiple projects of Drs. Wade Berrettini, Thomas Ferraro, and Falk Lohoff. Provided scientific leadership, technical training, and mentoring for team of four post-doctoral fellows, four research technicians, and five undergraduate students. Authored one manuscript for publication.* Nicotine Addiction (Dr. Berrettini). Re-sequenced (Sanger) exons of CHRNA5 and CHRNA3 for rare variants.* Opioid Use Disorder (OUD) (Dr. Berrettini). Consulted on opioid abuse projects studying μ-opioid receptor-interacting proteins. * Epilepsy (Dr. Ferraro). Designed genotyping assays for translational mouse models of epilepsy.* Bipolar Disorder & Schizophrenia (Dr. Lohoff). Developed monoamine uptake assays for functional analysis of VMAT1 variants.

Philadelphia, Pennsylvania, United States

Explored genetics of opioid use behaviors (mice and humans) and of bipolar disorder (humans). Supervised research projects by one post-doc as well as two graduate and three undergraduate students. Authored three manuscripts, one in-house, one private foundation (NARSAD), and two K-series mentored NIH grant proposals. * Human Opioid Studies. Initiated association studies of novel OPRM1 coding variants in opioid use disorder. * Mouse Opioid Studies. Expanded genetic map of μ-opioid receptor gene (Oprm) by discovering two new exons and eight new splice variants. Determined functional significance of genetic variants in Oprm promoter of mice with disparate oral morphine self-administration behavior. * Human Bipolar Disorder studies. Initiated candidate gene study of NDUFV2 in bipolar disorder. * Presented research findings at UPenn seminar series and at two meetings of the Society for Neuroscience.

Philadelphia, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Madison, Wisconsin, United States

Studied c-myc regulation as it relates to cancers, in particular breast cancer, in mice and humans. Trained two undergraduate students. Presented research at laboratory meetings, seminars, and one RNA Society meeting. * Mouse Studies. Cloned mouse c-myc coding region instability determinant binding protein (Crdbp) cDNA, and mapped structure of the mouse Crdbp gene. Designed / constructed Wap-Crdbp mini-gene expression vector to create transgenic mice that showed Crdbp over-expression in adult mammary epithelium leads to breast tumors in vivo; potentially a useful new model system for study of breast cancer therapeutics.* Human Studies. Localized human CRDBP (a.k.a. IMP-1, IGF2BP1) gene to chromosome 17q21, and discovered CRDBP gene is amplified in 30% of human breast cancers. * Authored two manuscripts, one book chapter, and one NCI grant application. Peer-reviewed one manuscript for top-level scientific journal.

Doctor Of Philosophy - Phd, Molecular Cell Biology

Dissertation Title: Transcriptional Regulation of Collagenase in Monocytic Cells * Elucidated the role of the AP-1 site in delayed.

Bachelor Of Arts - Ba, Biology; Cum Laude In Materia Subjecta, Cum Laude Generali

Activities and Societies: Phi Beta Kappa, Mu Chapter; Beta Beta Beta Biological Honor Society, Upsilon Tau Chapter